VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 1 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2023. The put-call ratio across all filers is - and the average weighting 2.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $236,000 | -83.0% | 10,000 | -81.8% | 0.02% | -77.9% |
| Q3 2016 | $1,385,000 | +24.2% | 55,000 | 0.0% | 0.07% | -32.7% |
| Q2 2016 | $1,115,000 | -85.5% | 55,000 | -25.7% | 0.10% | -73.8% |
| Q4 2015 | $7,692,000 | -39.6% | 74,000 | +0.3% | 0.38% | -43.5% |
| Q3 2015 | $12,732,000 | -16.7% | 73,800 | +6.6% | 0.68% | -13.2% |
| Q2 2015 | $15,285,000 | +10.1% | 69,200 | 0.0% | 0.79% | +18.4% |
| Q1 2015 | $13,879,000 | -21.8% | 69,200 | -44.6% | 0.66% | -17.3% |
| Q4 2014 | $17,739,000 | +8.6% | 125,000 | 0.0% | 0.80% | +6.5% |
| Q3 2014 | $16,333,000 | +14.2% | 125,000 | +10.6% | 0.75% | +20.8% |
| Q2 2014 | $14,299,000 | +19.2% | 113,000 | +22.2% | 0.62% | -29.7% |
| Q1 2014 | $11,998,000 | +25.8% | 92,500 | +12.8% | 0.89% | +58.3% |
| Q4 2013 | $9,536,000 | +10.9% | 82,000 | 0.0% | 0.56% | -7.0% |
| Q3 2013 | $8,597,000 | +23.4% | 82,000 | +12.3% | 0.60% | +14.9% |
| Q2 2013 | $6,967,000 | – | 73,000 | – | 0.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACCIPITER CAPITAL MANAGEMENT, LLC | 2,106,379 | $55,398,000 | 31.67% |
| Claren Road Asset Management, LLC | 80,000 | $2,820,000 | 24.27% |
| Okumus Fund Management Ltd. | 3,722,464 | $97,901,000 | 15.82% |
| Wingspan Investment Management, LP | 852,900 | $22,431,000 | 12.66% |
| FARLEY CAPITAL L.P. | 307,458 | $8,086,000 | 11.46% |
| Chou Associates Management | 976,843 | $25,725,000 | 8.35% |
| Wingspan Investment Management, LP | 550,700 | $14,483,000 | 8.17% |
| HAP Trading, LLC | 4,043,900 | $109,610,000 | 8.00% |
| LeVasseur Capital Partners LLC | 128,269 | $3,373,000 | 6.97% |
| Pershing Square Capital Management | 21,591,122 | $567,847,000 | 6.41% |